Breast cancer is characterized by distinct molecular subtypes based on receptor expression patterns—hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+)—which fundamentally influence treatment approaches and prognosis. Here, ERBB2 is linked to breast carcinoma.